Drug Trial Radar · NCT01923428
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
Last checked: Nov 19, 2026Latest source record: Apr 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
356
Actual
Start
Aug 2013
Primary completion
Oct 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- ArdelyxIndustry
- Sponsor type
- Industry
- First posted
- Aug 15, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III criteria and who have active disease as determined during a two-week screening period. Subjects who qualify and are randomized into the study will receive 5, 20, or 50 mg of AZD1722 BID or placebo BID for 12 consecutive weeks. At the end of this treatment period, subjects will be followed for an additional 4 weeks.
Conditions
- Constipation Predominant Irritable Bowel Syndrome
Interventions
AZD1722Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Complete Spontaneous Bowel Movement Responders vs PlaceboTime frame: 12 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Boulder, Colorado
Site not named
Greensboro, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Chattanooga, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.